
PXMD
Healthcare · Biotechnology · $88,385 market cap
$0.00070.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 29, 2024 | Time not confirmed | — | -0.10 | — |
| Sep 20, 2024 | Time not confirmed | -0.30 | -0.39 | -30.0% |
| May 13, 2024 | After the close | -0.43 | -0.50 | -16.3% |
| Mar 11, 2024 | After the close | -0.88 | -1.45 | -64.8% |
| Nov 16, 2023 | After the close | — | -5.20 | — |
| Aug 30, 2023 | Time not confirmed | — | -4.04 | — |
| Mar 30, 2023 | Time not confirmed | — | -0.41 | — |
| Nov 14, 2022 | Time not confirmed | — | -0.97 | — |
| Aug 29, 2022 | Time not confirmed | — | 0.11 | — |
| Jan 4, 2022 | Time not confirmed | — | -0.26 | — |
| Jul 2, 2020 | Time not confirmed | — | -0.06 | — |
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19…